ARCT-021

ARCT-021
Vaccine description
Target	COVID-19
Vaccine type	mRNA
Clinical data
Other names	Arcturus COVID-19 Vaccine, LUNAR-COV19
Routes of; administration	Intramuscular

ARCT-021, more commonly known as the LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.

Development

Phase I

Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.^[1] The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.^[2] LUNAR-COV19 clinical trials in humans began in July 2020.^[3]

Phase II

On 4 January 2021, Arcturus Therapeutics initially start the clinical trial phase 2.^[4]

References

^ "Coronavirus: Clinical trials for Singapore's vaccine project could start in August". The Straits Times. Retrieved 27 April 2020.
^ "With Arcturus, Catalent bags another COVID project". Bioprocess Insider. 6 May 2020. Retrieved 8 May 2020.
^ "Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects". clinicaltrials.gov. Retrieved 27 July 2020.
^ "Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the". Bloomberg. 4 January 2021. Retrieved 17 January 2021.

External links

Scholia has a profile for Lunar-COV19 (Q98713328).

[1] "Coronavirus: Clinical trials for Singapore's vaccine project could start in August". The Straits Times. Retrieved 27 April 2020.

[2] "With Arcturus, Catalent bags another COVID project". Bioprocess Insider. 6 May 2020. Retrieved 8 May 2020.

[3] "Phase 1/2 Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects". clinicaltrials.gov. Retrieved 27 July 2020.

[4] "Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the". Bloomberg. 4 January 2021. Retrieved 17 January 2021.

[1]

[2]

[3]

[4]